These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 36352154)

  • 21. Circ-CUL2/microRNA-888-5p/RB1CC1 axis participates in cisplatin resistance in NSCLC via repressing cell advancement.
    Chen H; Li F; Xue Q
    Bioengineered; 2022 Feb; 13(2):2828-2840. PubMed ID: 35068326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/MYH9 axis.
    Xu Y; Zhao R; Wang H; Jiang J; Wang Z; Wang J; Zhang W; Li M
    J BUON; 2021; 26(5):1850-1861. PubMed ID: 34761592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway.
    Shi SL; Zhang ZH
    Neoplasma; 2019 Sep; 66(5):756-765. PubMed ID: 31288529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circ_0010235 confers cisplatin resistance in lung cancer by upregulating E2F7 through absorbing miR-379-5p.
    Wang L; Wang D; Xu Z; Qiu Y; Chen G; Tan F
    Thorac Cancer; 2023 Jul; 14(20):1946-1957. PubMed ID: 37277864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circ_0004015 silencing represses cisplatin chemoresistance and tumor progression by reducing KLF8 in a miR-198-dependent manner in non-small cell lung cancer.
    Li Y; Yang X; Xiong X
    Genomics; 2022 Mar; 114(2):110294. PubMed ID: 35134495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
    Hua L; Zhu G; Wei J
    Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
    Pan X; Chen Y; Shen Y; Tantai J
    Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
    Wang L; Shang X; Feng Q
    Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer.
    Wu Y; Zhang J; Zhao J; Wang B
    BMC Pulm Med; 2024 Apr; 24(1):159. PubMed ID: 38561695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circular RNA hsa_circ_0068252 Functions in Cisplatin Resistance and Immune Response via miR-1304-5p/PD-L1 Axis in Non-Small Cell Lung Cancer.
    Li J; Xu J; Wu G; Ren Y; Wang X; Zhang Q
    Chemotherapy; 2022; 67(4):223-233. PubMed ID: 35649347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circular RNA SMARCA5 suppressed non-small cell lung cancer progression by regulating miR-670-5p/RBM24 axis.
    Zhang D; Ma Y; Ma Z; Liu S; Sun L; Li J; Zhao F; Li Y; Zhang J; Li S; Jiang J
    Acta Biochim Biophys Sin (Shanghai); 2020 Oct; 52(10):1071-1080. PubMed ID: 33085761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells.
    Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y
    Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion.
    Zhang BY; Han L; Tang YF; Zhang GX; Fan XL; Zhang JJ; Xue Q; Xu ZY
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):7015-7023. PubMed ID: 32633395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
    BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
    Pang J; Ye L; Zhao D; Zhao D; Chen Q
    Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLIDR-mediated regulation of tumor malignancy and cisplatin resistance in non-small cell lung cancer via the miR-342-5p/PPARGC1A axis.
    Liu R; Wang J; Zhang L; Wang S; Li X; Liu Y; Yu H
    BMC Cancer; 2024 Sep; 24(1):1126. PubMed ID: 39256686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. METTL3-mediated m6A modification promotes processing and maturation of
    Gong Y; Jiang Q; Liu L; Liao Q; Yu J; Xiang Z; Luo X
    Physiol Genomics; 2022 Sep; 54(9):337-349. PubMed ID: 35759451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer.
    Ren M; Song X; Niu J; Tang G; Sun Z; Li Y; Kong F
    Exp Cell Res; 2022 Oct; 419(2):113276. PubMed ID: 35863454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.